Premarket Movers Sept 30, 2026: CNTB, LGHL, VBIO

CNTB — Connect Biopharma Holdings Ltd (+84.0%)

Connect Biopharma (CNTB) is soaring roughly 84% to $1.84 in premarket trading this morning, with volume already hitting 84.9 million shares — nearly 38× its 20-day average of 2.2 million. That kind of premarket surge on this volume demands attention, even if the technicals were deeply depressed heading into today.

Why CNTB is up: The catalyst is clear. Connect Biopharma announced positive preliminary topline data from its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD (chronic obstructive pulmonary disease) and Type 2 inflammation. According to Yahoo Finance, the company reported fewer treatment failures in the trial. However, the picture is mixed: Stock Titan notes the study missed its lung-function target, and multiple headlines from StocksToTrade flag that analysts are trimming price targets following the mixed asthma data read-across. The reaction is a classic "mixed trial data bounce" — the market is seizing on the positive COPD signal while the fine print is still being digested.

Technical picture heading into today: The daily chart through September 29 tells a story of prolonged weakness. CNTB's RSI sat at 29 (near oversold territory), its moving-average stack was bearish, and the stock was sitting 72.9% below its 52-week high with an RS rating of just 13. StockSetups assigned a conviction score of 0/100 and a D grade — this was not a setup traders were watching for a technical breakout. The move today is entirely news-driven.

Short and smart-money context: The squeeze score is a modest 34/100 with a free float of 100% and short interest of roughly 1.99 million shares at 4.2 days to cover — not a classic heavily-shorted name, but enough short-side exposure that a gap this large can force covering and amplify the move. Insider James Huang purchased 150,000 shares ($372K) back in May 2026, and the consensus analyst price target as of September 27 stood at $6.86 — well above even today's premarket price, which may be adding fuel.

Risk note: Mixed trial data and analyst price-target cuts are a volatile combination. Stocks that gap this sharply on incomplete clinical readouts frequently give back a significant portion of the move once the regular session opens and sellers can react fully. This is a high-risk, news-driven name in a micro-cap biotech wrapper.

LGHL — Lion Group Holding Ltd (+51.7%)

Lion Group Holding (LGHL) is trading up 51.7% to $7.07 premarket, with 14.6 million shares changing hands against a 20-day average of just 166,515. That's nearly 88× normal premarket volume, an extreme surge for a company with a market cap of only $2.5 million.

Why LGHL is moving: The catalyst is unclear from the available data. The only recent filing on record is a 6-K (foreign private issuer report) filed September 29 with the SEC — classified as a neutral foreign event. No explanatory headline or press release has surfaced. With no confirmed catalyst, this move appears to be momentum- and technically-driven, likely sparked by the 6-K filing attracting attention among traders who monitor foreign issuer activity. Moves of this size on no confirmed news in micro-cap names are often the result of speculative retail momentum.

Technical picture heading into today: LGHL's prior-day chart was deeply distressed — RSI of 31, a bearish MA stack, a gap of -5.5%, and the stock sitting 99.1% below its 52-week high. RS rating of 1 is essentially the bottom of the universe. The conviction score is 0/100, grade D. There is no technical base here; the chart heading into today showed a stock in a prolonged downtrend.

Short and squeeze context: The squeeze score is 0/100 — essentially no meaningful short-side fuel. Short interest stands at only 188,711 shares with 0.0 days to cover, and short-volume is 24%. Crucially, a short-sale restriction (SSR) is active, meaning regulators have already flagged this stock's prior-session decline as significant enough to restrict aggressive shorting today. SSR can paradoxically amplify upside intraday momentum by removing short-side pressure. HRT Financial LP has been an accumulating buyer across multiple Form 4 filings in July–August 2026, though its stake sizes are modest.

Risk note: A +51.7% premarket move in a $2.5M market-cap name with no confirmed catalyst, 88× normal volume, and no technical support is one of the highest-risk setups on this list. These moves can reverse violently at the open. SSR does not prevent the stock from falling; it only restricts certain short-sale orders.

VBIO — Valion Bio, Inc. (+41.3%)

Valion Bio (VBIO) is up 41.3% to $4.00 premarket on 23.8 million shares — roughly 29× its 20-day average of 825,526. For a healthcare micro-cap with a $62.8M market cap, this kind of premarket activity is significant.

Why VBIO is moving: No headlines are on file for VBIO this morning, and no explanatory press release has been identified. The most recent SEC filings include a September 1 8-K flagged as dilutive (bearish) and a series of 13D/G stake-change filings in early September, suggesting active institutional positioning around the name. With no confirmed catalyst, this move looks technically and momentum-driven, potentially linked to the stake-change activity or speculative interest in the name following those filings.

Technical picture heading into today: Despite the chaos, VBIO's prior-day chart had one notable signal: a bullish engulfing candlestick — a two-candle reversal pattern where a green candle's body fully engulfs the prior red candle's body, suggesting buyers stepped in forcefully. RSI was at 41 (neutral, not overbought), and ADX at 48 indicates a strong existing trend. The stock was 91.5% below its 52-week high, and conviction was 0/100 with a D grade — but that engulfing candle was a rare bright spot on an otherwise bearish chart.

Short and squeeze context: The squeeze score is 41/100 with a free float of 98.5% and short interest of 340,186 shares. At only 0.4 days to cover, there isn't a ton of short-side fuel to squeeze — but short-volume running at 66% heading into the prior session means a meaningful portion of recent trading was short-side activity, which can add volatility when those positions cover into a spike. A 13D/G stake of up to 10.0% is disclosed, and the smart-money score is 25/100.

Risk note: The September 1 dilution event is a key risk factor that hasn't gone away. Stocks with recent dilutive 8-Ks that then spike on no news can attract sellers who see the premarket pop as an exit opportunity. The bullish engulfing pattern on the daily chart is a positive setup signal, but it was formed in deeply depressed price territory.

NCI — Neo-Concept International Group Holdings Ltd (+32.6%)

Neo-Concept International (NCI) is trading up 32.6% to $1.71 in premarket action on 8.35 million shares — about 8× its 20-day average of 1.03 million. The company operates in Consumer Discretionary with a market cap of $25.6 million.

Why NCI is moving: No specific catalyst has been identified this morning. The most recent headline (September 28, Stock Traders Daily) discusses NCI's price movement as an input in quantitative signal sets — not a fundamental catalyst. The most recent SEC filing is a 6-K from September 16 (neutral, foreign event). With no confirmed news, this move appears momentum-driven, possibly amplified by the stock's extremely low free float and its modest Reddit presence on r/pennystocks.

Technical picture heading into today: NCI's prior-day chart was in rough shape — RSI at 15, which is deeply oversold territory (below 30 is considered oversold; 15 is extreme). ADX of 35 confirms a strong trend, but in this case it's a bearish one. The stock was 98.7% below its 52-week high and carries a gap of -43.7%, meaning it has already experienced at least one severe prior gap down. Conviction sits at 8/100, grade D. The SSR restriction is active today.

Low-float dynamics: NCI's free float is only 16.5% — meaning only a fraction of its outstanding shares are freely tradable in the market. A low float (fewer shares available to buy and sell) means a relatively small amount of buying pressure can move the price dramatically, which is exactly what appears to be happening premarket. This is a double-edged sword: the same thin float that drives prices up quickly can send them down just as fast.

Short and squeeze context: The squeeze score is 49/100 — the highest on today's list — though short interest is only 120,264 shares at 0.1 days to cover, limiting the actual squeeze fuel. Short-volume was 53% in the prior session. The smart-money score is 27/100 with a largest disclosed stake of 5.0%.

Risk note: An RSI of 15, a prior gap down of -43.7%, SSR active, and no confirmed catalyst is a combination that demands extreme caution. These deeply oversold, low-float names can experience violent intraday reversals.

TGE — Generation Essentials Group (+22.0%)

Generation Essentials Group (TGE) is up 22.0% to $1.03 premarket on 22.5 million shares — an eye-popping 1,436× its 20-day average of just 15,686 shares. That ratio is the most extreme on today's list, making this effectively a previously dormant stock that has suddenly come to life.

Why TGE is moving: No headlines or explanatory filings are available. The only recent SEC activity is a 6-K filed September 11 (neutral, foreign event). With no confirmed catalyst and essentially zero baseline trading activity, this move is entirely unclear in origin — it appears to be pure momentum activity in a name with almost no prior liquidity. Market cap data is unavailable, which itself signals a very early-stage or thinly-followed issuer.

Technical picture heading into today: The daily chart through September 29 showed a deeply bearish setup — RSI at 39, a bearish MA stack, ADX of only 13 (trending weakly), and the stock sitting 60.7% below its 52-week high. The conviction score is 0/100, grade D. Technical rank of 19 and RS rating of 7 confirm this was not on any momentum trader's watchlist heading into this morning.

Short and squeeze context: The squeeze score is 26/100, with a free float of 24.2% — relatively low. Short interest is 71,032 shares with 5.0 days to cover, meaning it would take 5 days of average volume for short sellers to buy back their positions. In a name that averages 15,686 shares per day, short-volume of only 17% and a 5-day cover ratio suggests any forced covering could be disproportionately impactful. That said, the overall short interest is tiny in absolute terms.

Risk note: A stock that averages fewer than 16,000 shares per day suddenly printing 22.5 million shares premarket with zero confirmed catalyst is the definition of an unexplained spike. These situations carry the highest possible execution risk — wide bid-ask spreads, extreme volatility, and potential for immediate reversal. This is not a stock with a setup; it is a stock with a question mark.

The bottom line

This morning's premarket leaderboard spans the full spectrum of move types: a mixed-data biotech catalyst (CNTB), a mystery filing spike (LGHL), a technical-setup plus momentum play (VBIO), a low-float oversold bounce (NCI), and a dormant stock suddenly printing extraordinary volume for no apparent reason (TGE). Each carries its own specific risk profile — but all five share the universal risk of the premarket session itself.

Chasing premarket movers is high-risk. Premarket volume is a fraction of regular-session volume, meaning prices can be misleading. Spreads are wider, fills are harder, and the gap between the premarket price and the regular-session open can go either direction. Big premarket gainers frequently open lower than their premarket peak — or gap up further and then reverse sharply intraday. The VWAP fade setup is a real and common occurrence in names that spike like these.

Patterns and squeeze dynamics that look compelling at 7 AM ET can fail completely by 10 AM. Short-sale restrictions (active on LGHL and NCI) limit downside pressure temporarily but are not a guarantee of continued upside. Clinical trial data (CNTB) can be re-rated by analysts across the day. Dilution overhangs (VBIO) don't disappear because of a premarket pop.

Manage your risk. Size appropriately. Do your own research. Nothing here is a recommendation to buy or sell any security.

StockSetups scans the full ~12,300-stock US universe every premarket morning — surfacing movers like these, scoring their technical setups, flagging short-squeeze potential, and tracking smart-money signals — so you can see the landscape clearly before the open. For yesterday's after-close action, see our Top Stock Movers Sept 29, 2026 recap, and for yesterday's premarket, see Premarket Movers Sept 29, 2026.